当前位置：文档之家 › PF-04971729_1210344-57-2_DataSheet_MedChemExpress

PF-04971729_1210344-57-2_DataSheet_MedChemExpress

  • 格式：pdf
  • 大小：105.88 KB
  • 文档页数：1

Product Name:
PF-04971729CAS No.:
1210344-57-2Cat. No.:
HY-15461Product Data Sheet
MWt:
436.88Formula:
C22H25ClO7Purity :>98%
Solubility:
DMSO
Mechanisms:
Biological Activity:
PF-04971729(Ertugliflozin)is a potent and selective inhibitor of the sodium-dependent glucose Pathways:Membrane Tranporter/Ion Channel; Target:SGLT PF-04971729(Ertugliflozin) is a potent and selective inhibitor of the sodium-dependent glucose
cotransporter 2(SGLT2).
IC50 value:
Target: SGLT2PF-04971729 is currently in phase 2 trials for the treatment of diabetes mellitus. Inhibitory effects against the organic cation transporter 2-mediated uptake of [14C]metformin by PF-04971729 also were very weak (IC50 900μM).The disposition of PF-04971729, an orally active selective inhibitor of the sodium-dependent glucose cotransporter 2, was studied after a single 25-mg oral dose of [14C]-PF-04971729 to healthy human subjects. The absorption of PF-04971729 in humans was rapid with References:
[1]. Mascitti V, et al. Discovery of a clinical candidate from the structurally unique dioxa-
bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem.2011 Apr 28;54(8):2952-60.a Tmax at ~ 1.0 h. Of the total radioactivity excreted in feces and urine, unchanged PF-04971729collectively accounted for ~ 35.3% of the dose, suggestive of moderate metabolic elimination in humans....
p ;()[2]. Kalgutkar AS, et al. Preclinical species and human disposition of PF-04971729, a selective
inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of
type 2 diabetes mellitus. Drug Metab Dispos. 2011 Sep;39(9):1609-19.[3]. Miao Z, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin
(PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013 Feb;41(2):445-56.Caution: Not fully tested. For research purposes only
Medchemexpress LLC
18W i l k i n s o n W a y , P r i n c e t o n , N J 08540,U S A
E m a i l : i n f o @m e d c h e m e x p r e s s .c o m W e b : w w w .m e d c h e m e x p r e s s .c o m。

合集下载

MED-4920P

MED-4920P

MED-4920Liquid Silicone RubberSILICONE TECHNOLOGYCreative Partners in a Material WorldNuSil Technology 1050 Cindy Lane • Carpinteria, CA 93013 805/684-8780 • 805/566-9905 Fax An ISO 9001 Certified CompanyProduct ProfileDescription• • • Two-part, translucent silicone system used with injection molding equipment Rapid cure with no post-cure required 1:1 Mix Ratio (Part A:B)Applications• For the injection molding of parts requiring a material with a low durometer, including: gaskets, seals, molded balloons, and catheter tipsNuSil Technology’s MED-4920 is a restricted product. It shall not be considered for use in human implantation for a period of greater than 29 days.ResultTranslucent 35 g/min 40 g/min >24 hours 1.13 20 1,000 psi 900% 125 ppi 65 psiTypical PropertiesUncured: Appearance Extrusion Rate*, Part A Extrusion Rate*, Part B Work Time Cured: 5 minutes @ 150°C (302°F) Specific Gravity Durometer, Type A Tensile Strength Elongation Tear Strength Stress @ 200% StrainMetric Conv.6.9 MPa 22.0 kN/m 0.4 MPaASTMD2090 C603 C603 D792 D2240 D412, D882 D412, D882 D624 D412, D882NT-TM002 033 033 008 003 006 007 007 009 007* Performed using a SEMCO 440 nozzle with a 1/8” orifice and 90+/-5 psi air pressureInstructions for UseMixingUse with mix and dispense equipment in a 1:1 mix ratio. If mixing by hand, take care to minimize air entrapment.Packaging50 ml SxS Kit 400 ml SxS Kit 2 Pint Kit (910 g) 2 Gallon Kit (7.28 kg) 10 Gallon Kit (36.4 kg)Vacuum DeaerationRemove air entrapped during mixing by common vacuum deaeration procedure, observing all applicable safety precautions. Slowly apply vacuum, up to 28 inches Hg, to a container rated for use and of volume at least four times that of material being deaerated. Hold vacuum until presence of air is no longer evident.Warranty12 MonthsSubstrate ConsiderationCures in contact with most materials common to biomedical assemblies. Exceptions include butyl, latex, chlorinated rubbers, some RTV silicones and unreacted residues of some curing agents.Adjustable Cure ScheduleProduct cures at a wide range of cure times and temperatures to accommodate different production needs. Contact NuSil Technology for details.MED-4920 05 April 2007FDA Master Access FileA Master Access File for MED-4920 has been filed with the U.S. Food and Drug Administration. Customers interested in authorization to reference the Master Access File must contact NuSil Technology.Warnings About Product SafetyNuSil Technology believes that the information and the data contained herein are accurate and reliable. However, the user is responsible to determine the material’s suitability and safety of use. NuSil Technology cannot know each application’s specific requirements and hereby notifies the user that it has not tested or determined this material’s suitability or safety for use in any application. The user is responsible to adequately test and determine the safety and suitability for their application and NuSil Technology makes no warranty concerning fitness for any use or purpose. NuSil Technology has completed no testing to establish safety of use in any medical application. NuSil Technology has tested this material only to determine if the product meets the applicable specifications. (Please contact NuSil Technology for assistance and recommendations when establishing specifications.) When considering the use of NuSil Technology products in a particular application, review the latest Material Safety Data Sheet and contact NuSil Technology with any questions about product safety information. Do not use any chemical in a food, drug, cosmetic, or medical application or process until having determined the safety and legality of the use. The user is responsible to meet the requirements of the U.S. Food and Drug Administration (FDA) and any other regulatory agencies. Before handling any other materials mentioned in the text, obtain available product safety information and take the necessary steps to ensure safety of use.SpecificationsDo not use the typical properties shown in this technical profile as a basis for preparing specifications. Please contact NuSil Technology for assistance and recommendations in establishing particular specifications.Patent WarningNuSil Technology disclaims any expressed or implied warranty against the infringement of any patent. NuSil Technology does not warrant the use or sale of the products described herein will not infringe the claims of any United States’ or other country’s patents covering the product itself, its use in combination with other products or its use in the operation of any process.Warranty InformationNuSil Technology’s warranty period is 12 months from the date of shipment when stored below 40°C in original unopened containers. Unless NuSil Technology provides a specific written warranty of fitness for a particular use, NuSil Technology’s sole warranty is that the product will meet NuSil Technology’s then current specification. NuSil Technology specifically disclaims any other expressed or implied warranty, including warranties of merchantability and fitness for use. The exclusive remedy and NuSil Technology’s sole liability for breach of warranty is limited to refund of purchase price or replacement of any product shown to be other than as warranted. NuSil Technology expressly disclaims any liability for incidental or consequential damages.MED-4920 05 April 2007。

富马酸替诺福韦酯杂质 标准品 对照品

富马酸替诺福韦酯杂质 标准品 对照品

富马酸替诺福韦酯是一种化学物质，核苷酸逆转录酶抑制剂，是替诺福韦（PMPA，2）的前药，临床主要用于治疗人类免疫缺陷病毒（HIV）感染。

富马酸替诺福韦酯标准品列表名称结构式替诺福韦单异丙氧碳酸甲基酯Tenofovir Disoproxil RelatedCompound ECAS:211364-69-1替诺福韦酯异丙氧碳酸甲基甲基酯CAS: 1246812-16-7替诺福韦异丙氧碳酸甲基甲氧碳酸甲基酯Mono-POC Methyl TenofovirCAS: 1246812-43-0Tenofovir Impurity Q替诺福韦异丙氧碳酸甲基异丙基酯Tenofovir Disoproxil RelatedCompound GCAS: 1422284-15-8替诺福韦-N-异丙氧羰基异丙氧碳酸甲基酯Tenofovir Impurity ECAS:1244022-56-7替诺福韦酯杂质FTenofovir Impurity F（S）-替诺福韦二异丙氧碳酸甲基酯替诺福韦异丙氧碳酸甲基丙基碳酸甲基酯CAS: 1217542-13-6替诺福韦二聚物单酯CAS:1093279-77-6替诺福韦二聚物Tenofovir Disoproxil DimerCAS:1093279-76-59-丙烯腺嘌呤Tenofovir Disoproxil RelatedCompound BCAS：4121-40-8替诺福韦酯杂质RTenofovir Impurity R替诺福韦异丙氧碳酸甲基乙基碳酸甲基酯替诺福韦二乙酯Tenofovir impurity V替诺福韦单乙酯Tenofovir DisoproxilCarbamateDiethylaminocarboxymethylPOC Tenofovir Fumarate6N-Hydroxymethyl TenofovirDisoproxil1244022-53-4Isopropyl Tenofovir Diisopropyl Tenofovir Fumarate 160616-04-6 (free base)(S)-Tenofovir147127-19-3替诺福韦酯杂质R6N-Bromomethyl TenofovirDisoproxilTenofovir Disoproxil Fumarate Impurity(N6-CH2OH-POC PMPA) Tenofovir Related Compound 2 379270-35-6Tenofovir Related Compound 352364-31-5Tenofovir Related Compound 4851456-00-3Tenofovir Related Compound 51234081-04-9 Tenofovir Related Compound 6 383365-04-6Tenofovir Related Compound 7 79487-89-1Tenofovir monophosphate 206646-04-0Tenofovir Diphosphate166403-66-3Tenofovir Trimer Impurity 1Tenofovir Trimer Impurity 2。

VerifyNow基本介绍

VerifyNow基本介绍

2
PRU >208 (n=3610) PRU ≤208 (n=4839)
Stent thrombosis (def/prob) (%)
HR [95%CI] = 2.54 [1.55, 4.16] P=0.0001
1.3%
1
0.5%
0
0
Number at risk: PRU > 208 PRU ≤ 208 3610 4839
PRU 与不良临床事件发生的关系
50 Ischemic end point (iep) Bleeding end point (bep) 40 30 20 10 0 p<0.01
Incidence of events (%)
PRU 85
75 (25%) pts 1 (1.3%) iep 15 (20%) bep
• 在药物浓度达到平衡后,人体在一天的时间内,
PRU值会有大约±10% 自然生理变化波动
– “最高值” 和 “最低值” 相差10%左右
– Meta-Analysis 研究显示病人剩余血小板聚集活性高的,其发生严重心血管事件(如心血管 死亡,心梗,支架栓塞)的风险升高2倍. – ADAPT-DES研究则显示,病人剩余血小板聚集活性高的,其在30天内发生支架栓塞的风险升 高4倍, 而且高剩余血小板聚集活性(HRPR)是超过30%的事件的发生的直接独立因素.
随阿司匹林剂量增加,药物抵抗的比例降低
ASA Responsiveness and dose 100% 0
Percentage of patients
80% 60% 40% 20% 0%
30.2
16.7
69.8
83.3
100
ASA-R ASA-S
纯化线粒体呼吸控制率RCR定量检测试剂盒说明书

纯化线粒体呼吸控制率RCR定量检测试剂盒说明书

活体细胞线粒体形态/活性荧光染色试剂盒
植物组织线粒体形态/活性荧光染色试剂盒
真菌/酵母细胞线粒体形态/活性荧光染色试剂盒
活体细胞线粒体跟踪试剂盒 活体细胞线粒体长期跟踪试剂盒
全血线粒体 DNA 萃取试剂盒 纯化线粒体 DNA 萃取试剂盒 细胞/组织线粒体 DNA 萃取试剂盒 细胞/组织基因组/线粒体 DNA 同步萃取试剂盒 动物血小板线粒体 DNA 萃取试剂盒 真菌/酵母细胞线粒体 DNA 萃取试剂盒 植物线粒体 DNA 萃取试剂盒 动物硬组织线粒体 DNA 萃取试剂盒 非突触体脑组织线粒体分离试剂盒 植物线粒体粗提分离试剂盒 植物活性线粒体分离试剂盒 植物高质纯化线粒体分离试剂盒 真菌/酵母细胞线粒体粗提分离试剂盒 真菌/酵母细胞活性线粒体分离试剂盒 真菌/酵母细胞高质纯化线粒体分离试剂盒 细胞 ATP 生物发光法定量检测试剂盒 纯化线粒体蛋白质浓度定量测定试剂盒 动物血小板线粒体粗提分离试剂盒 动物血小板活性线粒体分离试剂盒 动物血小板高质纯化线粒体分离试剂盒 动物全血线粒体粗提分离试剂盒 动物全血活性线粒体分离试剂盒 动物全血高质纯化线粒体分离试剂盒 超氧化物歧化酶（SOD）活性检测试剂盒 线粒体超氧化物歧化酶（Mn/Fe SOD）分离试剂盒 超氧化物歧化酶（SOD）标准曲线测定试剂盒 纯化线粒体可溶性总蛋白制备试剂盒 细胞/组织线粒体可溶性总蛋白制备试剂盒 真菌/酵母细胞线粒体可溶性总蛋白制备试剂盒 植物线粒体可溶性总蛋白制备试剂盒 全血线粒体可溶性总蛋白制备试剂盒
技术背景
线粒体是细胞呼吸链和氧化磷酸化的中心。电子传递和ATP合成通过质子梯度偶联成一体。线粒体结构完 整，功能正常，底物充分，电子传递形成的质子梯度不断被消耗，电子得以顺畅传递，氧气快速消耗，其 耗氧率大，为III态呼吸。ADP耗竭，质子梯度不能消耗，阻碍电子传递，氧气消耗减少，为IV态呼吸。 呼 吸控制率（respiratory control ratio或respiratory control index；RCR），又称呼吸调节比，是指III态（加入ADP） 的呼吸速率与IV态（ADP耗竭）的呼吸速率之比。正常线粒体的RCR为3至10：RCR降低意味着线粒体ATP 合成功能损伤，呼吸障碍；RCR增高意味着细胞活动旺盛，代谢加快。